Business
NanoViricides, Inc. Has Filed its Annual Report
Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections SHELTON, CONNECTICUT / ACCESS Newswire / September 30, 2025 / NanoViricides, Inc. (NYSE American:NNVC) ...
About this update from Nanoviricides, Inc.
[{"type":"text","content":"Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage - NV-387 Could Become a Revolutionary Antiviral for Respiratory Viral Infections","length":145,"tagName":"p"},{"type":"text","content":"SHELTON, CONNECTICUT / ACCESS Newswire / September 30, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2025 with the Securities and Exchange Commission (SEC) on Monday, September 29, 2025. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000110465925094527/nnvc-20250630x10k.htm).","length":446,"tagName":"p"},{"type":"text","content":"In the fiscal year 2025, we have achieved a substantial level of accomplishments. We have focused on evaluating the broad spectrum of antiviral activity of NV- 387.","length":164,"tagName":"p"},{"type":"text","content":"We believe that NV-387 is on its way to become a revolutionary antiviral therapy that could be prescribed for practically any respiratory viral infection without first testing for the causative virus, just as broad-spectrum antibiotics can be prescribed even before testing for the causative bacteria. This "emperic therapy" approach would enable immediate treatment and thus improve effectiveness; it is well known that antiviral treatments are most effective when given early.","length":488,"tagName":"p"},{"type":"text","content":"NV-387 would play in a market size of well over $20 Billion as a dominant player, if approved for such emperic therapy of viral ARI/SARI.","length":137,"tagName":"p"},{"type":"text","content":"To this end, we have proposed a novel adaptive, Phase II clinical trial for the evaluation of NV-387 as a treatment for Viral Acute/Severe Acute Respiratory Infections (V-ARI, V-SARI) towards this goal. A preliminary clinical protocol for this complex trial has been developed.","length":277,"tagName":"p"},{"type":"text","content":"At present, we are fully engaged in completing the Clinical Trial Application (CTA) for a Phase II clinical trial of NV-387 for the treatment of MPox disease in Africa. MPox continues to spread and surge in African countries and is endemic in the Democratic Republic of Congo (DRC) and neighboring countries. Due to this, African CDC has continued its declaration of Public Hea...